FDA isn't lifting the clinical hold on Solid Bio's Duchenne MD gene therapy just yet — but is there a silver lining?
It may now be close to a year before Solid Bio can resume human testing on its lead gene therapy program.
The clinical hold that the FDA slapped on the program last November in the wake of a severe adverse event marked the second such interruption for the Phase I/II IGNITE DMD study, which was testing SGT-001 in a small cohort of patients with Duchenne muscular dystrophy. While Solid Bio resolved the first hold within three months, this time around regulators demanded more data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
